



이름: 박준규/Jun-Kyu Park

직위: 수석팀장/Senior Team Leader

소속: (주)시지바이오/CG Bio Co., Ltd.

기타소속:

강연제목: 시롤리무스와 아스코빅산이 용출되는 관상동맥용스텐트/Sriolimus and Ascorbic acid-eluting Coronary Stent Systems

Abstract:

Coronary arterial stenting with drug-eluting stents (DES) is a primary treatment method for coronary arterial diseases in current interventional cardiology practice. It has been reported that dual DES can overcome the problems of single DES, including in-stent restenosis, thrombosis, and anti-endothelialization. Sirolimus and ascorbic acid-eluting stent systems has an optimized platform and coating technology, so it is expected to be effective in treating coronary artery disease. The non-inferiority of the stent compared to the BioMatrix Flex stent was demonstrated in the comparative evaluation of the mean intra-segmental late loss at 36 weeks compared to the baseline on coronary angiography, which is the primary efficacy endpoint after application of the clinical trial medical device, and the safety result was also CGBIO There is no difference in the occurrence of adverse events between the stent and the BioMatrix Flex stent, so it is expected as a drug-releasing stent for the treatment of patients with coronary artery disease.

Brief Biosketch

2011 ~ 현재 R&D center at CGBio Co Ltd.

Research fields: Interventional Medical devices (Coronary Stent, Catheter etc.)

Miwon Commercial Young Scientist Award, 2019.10.31, Korea Society of Industrial and Engineering Chemistry, Young Scientist Award, 2018.04.05, The Polymer Society of Korea, Ministry of Health and Welfare Award. 2021.11.24